About the Cover
Cover image
Cover: Presence of hydrogen peroxide (H2O2; orange) in the gut of Drosophila melanogaster following infection. Bandarra et al. identified a novel function of the mammalian hypoxia-inducible factor (HIF) and the Drosophila homologue (Sima) in restraining the major inflammation-responsive transcription factor, nuclear factor κB (NF-κB). H2O2 levels were increased in sima loss-of-function transgenic flies following Serratia marcescens infection. HIF-1α was identified as an inhibitor of NF-κB activity, and could therefore be important in preventing excessive and harmful pro-inflammatory responses. See article by Bandarra et al. on page 169.
This issue
Other journals from The Company of Biologists
Subject collection - Human host-microbiome interactions in health and disease
Imbalances or alterations in the composition of our microbiome are now implicated in many disease states. This new collection of review and research articles gives a snapshot of the complexity of the microbiome and its role in maintaining human health.
Editor’s choice – Generation of mouse-zebrafish hematopoietic tissue chimeric embryos for hematopoiesis and host-pathogen interaction studies
In our Editor’s choice this month, Miguel L. Allende and colleagues have developed a xenotransplantation technique to generate hundreds of zebrafish chimeras with distinct phenotypes of murine blood cells in both circulation and the hematopoietic niche. This enables direct visualization of blood cell function and migration in living organisms.
Featured article - Cooperation of loss of NKX3.1 and inflammation in prostate cancer initiation
Cory Abate-Shen and colleagues demonstrate a reciprocal relationship between inflammation and the status of the NKX3.1 homeobox gene associated with prostate cancer initiation in their Research Article. They propose that loss of function of NKX3.1 accelerates inflammation-driven prostate cancer initiation potentially via aberrant cellular plasticity and impairment of cellular differentiation.
Review - Dissecting human disease with single-cell omics: application in model systems and in the clinic
In this Review, Ana Cvejic and colleagues summarise the current state of the art of single-cell techniques and their potential applications in deciphering the heterogeneous nature of diseases and tailoring personalised therapies.
First Person interviews
Have you seen our interviews with the early-career first authors of our papers? The authors talk about their work in and out of the lab, the journeys that led them to where they are now and the scientists who inspired them along the way. Recently, we caught up with Sudipta Bar, first author of ‘Neuromuscular degeneration and locomotor deficit in a Drosophila model of mucopolysaccharidosis VII is attenuated by treatment with resveratrol’.
Journal meeting – Blood disorders: models, mechanisms and therapies
Register your interest in our upcoming meeting on blood disorders and their treatment, organised by DMM Editor-in-Chief Monica Justice, Nancy Speck, Paresh Vyas and Leonard Zon. The meeting will bring together diverse front-line researchers, stimulating discussions across basic research and clinical disciplines, and fostering collaborative links among researchers.
Why should you publish your next paper in DMM?
DMM aims to promote human health by encouraging collaboration between basic and clinical researchers, covering a diverse range of diseases, approaches and models. Our Editors are all active researchers in the field – your peers, colleagues and mentors, who know how much work has gone into every paper. Recently, we have introduced format-free submission, and we accept peer review reports from other journals, making submission as easy as possible for our authors. Send us your next great paper – publish with us and you'll be in good company.
preLights – The landscape of antigen-specific T cells in human cancers
Identifying the specific targets of T cells that can destroy cancer cells is a priority in the field of immunotherapy. Rob Hynds highlights a recent preprint where the authors use a clustering approach in pan-cancer RNAseq datasets to discover new recurrent targets.